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Objectives: The aim of the Consensus on Health Economic Criteria (CHEC) project is to
develop a criteria list for assessment of the methodological quality of economic
evaluations in systematic reviews. The criteria list resulting from this CHEC project should
be regarded as a minimum standard.
Methods: The criteria list has been developed using a Delphi method. Three Delphi
rounds were needed to reach consensus. Twenty-three international experts participated
in the Delphi panel.
Results: The Delphi panel achieved consensus over a generic core set of items for the
quality assessment of economic evaluations. Each item of the CHEC-list was formulated
as a question that can be answered by yes or no. To standardize the interpretation of the
list and facilitate its use, the project team also provided an operationalization of the criteria
list items.
Conclusions: There was consensus among a group of international experts regarding a
core set of items that can be used to assess the quality of economic evaluations in
systematic reviews. Using this checklist will make future systematic reviews of economic
evaluations more transparent, informative, and comparable. Consequently, researchers
and policy-makers might use these systematic reviews more easily. The CHEC-list can be
downloaded freely from http://www.beoz.unimaas.nl/chec/.
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Health-care professionals, consumers, researchers, and
policy-makers can be overwhelmed by the sometimes un-
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manageably large number of trials and economic evaluations
of health care interventions. Systematic reviews of these stud-
ies can help in making well-informed decisions on which
intervention to adopt. For maximum usefulness, systematic
reviews of economic evaluations should be transparent, that
is, all relevant methodological information from the included
studies should be described in a systematic way. However,
there is no generally accepted criteria list for reviewing eco-
nomic evaluations, which may be because most of the criteria
lists are created single-handed. The aim of the Consensus on
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Health Economic Criteria (CHEC) project was to develop a
generally accepted criteria list, which should be regarded as
a minimum standard.
The CHEC-list focuses only on the methodological qual-
ity of economic evaluation aspects, as existing criteria lists
focus already on the methodological quality of more gen-
eral aspects of effectiveness studies (20;23). The CHEC-list
was developed for systematic reviews of full economic eval-
uations based on effectiveness studies (cohort studies, case-
control studies, randomized controlled trials). The focus on
economic evaluations alongside trials is due to practical con-
siderations, because other methodological criteria are rele-
vant when using other designs, for example, modeling studies
or scenario analyses (27). The criteria list has been developed
using a Delphi method. A similar method was used in devel-
opment of an instrument to assess the methodological quality
of randomized controlled studies (30).
METHODS
The study started with the creation of a large item pool,
followed by reduction by a Delphi method. In this study, three
Delphi rounds were sufficient to reach consensus (defined as
general agreement on a substantial majority).
The project team was responsible for the construction
and reduction of the item pool, the selection of participants
of the Delphi panel, the construction of the Delphi question-
naires, the analysis of the response, and the formulation of
the feedback.
Construction and Reduction of the
Item Pool
For the development of the initial item pool, items were
selected from various sources, and several search strategies
were used to identify the relevant literature in the field of eco-
nomic evaluations. First, a Medline search was performed for
the period 1990 to 2000 using MESH headings “cost and cost
analysis,” “meta-analysis or review literature.” Additionally,
Psychlit and Econlit were screened for the same period using
keywords “review or meta-analysis” and “economic or cost”
in titles. Additional articles were identified by searching the
Cochrane Library (2000, issue 3) and the National Health
Service EED database using the terms “cost or economic.”
Finally, handbooks on economic evaluations were monitored
and a request to submit additional guidelines was presented
to the HealthEcon Discussion List.
Three members of the team (S.E., M.G., and A.A.) de-
veloped a classification scheme, which included the vari-
ous domains of economic evaluations (e.g., economic study
question, economic study design, economic identification,
outcome valuation) under which all items were ordered. The
classification scheme consisted of nineteen categories. De-
tails of the methods have been published elsewhere (2). The
Delphi participants were given the opportunity in the first
Delphi round to add additional categories and items they
thought were missing.
Selection of Participants
Twenty-three international experts participated in our Delphi
panel (see acknowledgments). We first formed a Task Force
Group consisting of seven international experts in the field
of economic evaluations. This Task Force Group assisted the
project team with the composition of the final Delphi panel.
Participants for the Delphi panel were selected if they were
authors of guidelines or criteria lists or if they had special
expertise in (systematic reviews of) economic evaluations.
The project team made a first selection, keeping a balance
between various countries and research groups. The inclusion
of experts from different research settings all over the world
was an explicit goal. The final Delphi panel was approved by
the Task Force Group.
Procedure/Analysis
During the entire Delphi procedure, structured questions
were combined with open questions to facilitate the Delphi
process. For example, in the Delphi-1 questionnaire, partici-
pants were asked to indicate which categories should be in-
corporated in a minimum set of the criteria list and give their
arguments. Participants were always asked for other sugges-
tions. In all the Delphi rounds, participants were asked to
complete the questionnaire “bearing in mind the aim of the
project.” After each Delphi round, feedback was given to in-
form the participants of decisions, opinions, and arguments
of the other participants. The project team decided, on the
basis of the majority of the answers and the arguments used,
which categories and items should appear in the next Delphi
round. Overall, a category or item was included based on
an arbitrary cutoff point (if half of the participant plus one
agreed on its inclusion).
The decisions of the project team were also presented
and justified in feedback reports (Delphi questionnaires,
feedback reports, and the final CHEC-list can be downloaded
from www.beoz.unimaas.nl/chec/).
Delphi Rounds
In the first Delphi round, participants were asked to indicate
which categories and subsequently which items should be
included in the CHEC-list. In the second Delphi round, the
participants received the results and comments of the panel
together with the decisions of the project team. In this second
Delphi round, participants were asked, “to select one item of
each category that should be included in the final CHEC-
list.” Based on the analysis of this second round, the project
team phrased a concept version of the CHEC-list. In the third
Delphi round, participants were given a final opportunity to
suggest modifications to the concept version of the CHEC-
list.
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 21:2, 2005 241
Evers et al.
Pilot
To pilot the applicability of the CHEC-list, two articles on
economic evaluations were reviewed by all authors.
RESULTS
Participants
Twenty-six experts were invited to participate in the Delphi
panel, of whom two did not accept the invitation and one
who originally agreed to participate did not respond to our
questionnaires. A total of twenty-three members completed
all three Delphi rounds.
Delphi-1 Round
A total of twenty-five guidelines were initially identified (1;
3–22;24–26;28;29). Five of these guidelines were excluded
after reading, because they were inadequate for our goal
(3;5;14;22;28). Furthermore, some guidelines were pub-
lished more than once (4;7;10;11;24–26). This finding left
a sample of fifteen guidelines available, resulting in an ini-
tial item pool of 218 items. The item pool was restructured
and reduced using the classification scheme. We eliminated
items on general methodology (covered by criteria lists of
effectiveness studies), and skipped (almost) identical for-
mulations (see Ament et al. [2]). This strategy reduced the
initial item pool to 128 items spread over nineteen categories,
which were used in the first Delphi round. In the first Delphi
round, all nineteen categories were considered essential for
the CHEC-list, that is, the lowest approval (83 percent) was
on the category “Ethics and distributional effects.” The items
to be included in each category, however, did show some
major differences (agreement varied between 9 percent and
91 percent). We used a majority agreement as an arbitrary
cutoff point to include an item within a category. If none
of the items reached the cutoff point within a category, the
project team decided on the most appropriate item based on
the arguments of the participants in the first Delphi round.
Delphi-2 Round
On the basis of the results of the Delphi-1, the project team
created a feedback report and a Delphi-2 questionnaire, in
which all items that met the above criteria were presented
to the participants. All twenty-three participants completed
and returned the Delphi-2 questionnaire. In the analysis
within each category, the item with the highest percentage of
agreement was chosen. An important observation from the
Delphi-2 round was that a large number of the participants
indicated that they preferred items to be selected that give
insight into the quality of the study performed, rather than
into how the study is performed (e.g., “Is the economic study
design appropriate to the stated objective?” instead of “What
is the form of design used?”). The project team selected
and rephrased items and developed a concept version of the
CHEC-list, which was included in the Delphi-3 question-
naire. In addition, guidelines were developed on how to fill
out the CHEC-list, which gave an explanation of the meaning
of each item.
Delphi-3 Round
The Delphi-3 questionnaire was also completed and returned
by all twenty-three participants. The majority of the partici-
pants accepted the concept CHEC-list. To give a taste of the
final discussion, we present some examples of the remarks of
the panel members. Some participants had specific comments
regarding the category “Presentation of results.” Three items
in this category were included in the Delphi-2 questionnaire,
that is, “Are the methods and analysis displayed in a clear
and transparent manner?,” “Do the conclusions follow from
the data reported?,” and “Are the assumptions and limitations
of the study discussed?.” The agreement of these items was
39.1 percent, 69.6 percent, and 26.1 percent, respectively.
We, therefore, had selected item 2 for our final CHEC-list
(see Table 1). In the second and the third Delphi round, three
Delphi members suggested that all three items should be re-
tained in the criteria list. The project team reconsidered this
and decided, as it was only suggested by the minority to keep
to their original decision based on the opinion of the majority
of the panel members.
In the guideline of the CHEC-list, regarding the category
“perspective,” the project team had stated the following “If
the study is performed from a societal perspective tick ‘yes,’
as all relevant costs and consequences of an intervention and
disease are taken into account, if possible. Other narrower
perspectives will only include certain components. The au-
thors should motivate why a narrower perspective is valid.”
Based on this statement, one participant remarked that “there
is no single appropriate perspective. What is appropriate de-
pends upon the decision/policy-maker. Thus, the answer to
this item, if answerable at all, will be use-context specific and
not intrinsic to the published study.” Although we agree to a
certain extent with the remarks made by this Delphi mem-
ber, it is an overall limitation of any criteria list to design a
general criteria list, in which all items are equally relevant
for all studies. Based on the discussion in the project team,
we decided to not alter the guidelines and the CHEC-list, as
the majority of the Delphi panel agreed with the suggested
phrasing.
Regarding the category “independence of the investiga-
tor” one participant also remarked that “A study should not
be ‘marked down’ because there are acknowledged potential
conflicts. If we do that, no studies published by the phar-
maceutical industry or by organizations working for them
would be acceptable.” Based on this, the project team did not
change the item, but in the explanation, we tried to overcome
this difficulty by stating that “If an external agency finances
the study, a statement should explicitly be given about who
finances the study to guarantee transparency in the relation-
ship between the sponsor and the researcher. Whenever a
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Table 1. Final CHEC-List after Three Delphi Rounds
Agreement
On inclusion of On inclusion of
Items finally included in the CHEC-list As decided upon in the Delphi 3 category Delphi 1 this item Delphi 2
1. Is the study population clearly described? 100% 65.2%
2. Are competing alternatives clearly described? 100% 69.6%
3. Is a well-defined research question posed in answerable form? 91% 100%a
4. Is the economic study design appropriate to the stated objective? 91% —b
5. Is the chosen time horizon appropriate to include relevant costs and 100% 69.6%
consequences?
6. Is the actual perspective chosen appropriate? 100% —b
7. Are all important and relevant costs for each alternative identified? 100% 82.6%3
8. Are all costs measured appropriately in physical units? 96% 73.3%3
9. Are costs valued appropriately? 96% —b
10. Are all important and relevant outcomes for each alternative identified? 100% 100%a
11. Are all outcomes measured appropriately? 96% —b
12. Are outcomes valued appropriately? 96% —b
13. Is an incremental analysis of costs and outcomes of alternatives performed? 87% 100%a
14. Are all future costs and outcomes discounted appropriately? 100% —b
15. Are all important variables, whose values are uncertain, appropriately subjected 100% —b
to sensitivity analysis?
16. Do the conclusions follow from the data reported? 100% 69.6%
17. Does the study discuss the generalizability of the results to other settings and 91% 78.3%
patient/client groups?
18. Does the article indicate that there is no potential conflict of interest of study 91% 56.5%c
researcher(s) and funder(s)?
19. Are ethical and distributional issues discussed appropriately? 83% 100%a
a This was the only item left in the Delphi-2 questionnaire.
b Based on the discussion, this item was rephrased and agreed upon in the Delphi-3 round.
c Agreement was high, but based on the discussion, the item was somewhat rephrased and agreed upon in the Delphi-3 round.
CHEC, Consensus on Health Economic Criteria.
potential conflict of interest is possible, a declaration should
be given of ‘competing interest’.”
Pilot
The pilot test of the CHEC-list showed a strong agreement
among the assessments of the members of the project team
when reviewing two articles. No items were changed or
adapted.
CONCLUSION
This study is the first in which a broadly accepted crite-
ria list for economic evaluations was developed based on
a Delphi consensus procedure. In a consensus procedure,
the choice of participants is crucial. In the selection of this
Delphi panel, the project group tried to achieve a broad rep-
resentation of experts on quality assessment of economic
evaluations. In the Delphi-2 round, it became clear that the
majority of the participants wanted the CHEC-list to in-
clude items that give insight into the quality of economic
evaluations rather than into how the economic evaluation
is performed. As a result, most of the items included are
now subjective judgments, not simple statements of “fact.”
In its practical use, this may challenge the inter-rater vari-
ability. The project team, therefore, suggests using two or
more reviewers when performing a systematic review and
conducting a pilot test. Criteria lists, such as the CHEC,
can be criticized because of their potential rigidity, which
might prohibit further development of methodology. This
criticism is only valid if criteria are used injudiciously. To
prevent the CHEC-list from being methodologically rigid,
the project group emphasizes that the CHEC-list is a mini-
mum set and would like to stimulate researchers to add addi-
tional items appropriate for the specific subject under study, if
relevant.
Finally, there are many examples of poor reporting of
economic evaluations. It is often difficult to conclude what
actually happened in the study and this affects the method-
ological quality assessment. Part of the problem is because
journals only accept a limited number of words in an arti-
cle, thus making extensive explanations almost impossible.
A solution might be to contact the authors of the original
study, asking them for a more detailed description of the
study design. An alternative would be to require the pro-
duction of a standard technical report for every economic
evaluation study. This technical report should be available
to everyone, for example on the Internet. Such a technical
report, describing the economic design, and details of the
study, could also be used in systematic reviews.
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Notwithstanding these limitations, we believe that, by
creating a criteria list consisting of a minimum set of items,
this CHEC-list makes it possible for future systematic re-
views of economic evaluations to become more transparent,
informative, and comparable.
Policy Implications
There was consensus among a group of international experts
regarding a core set of items that can be used to assess the
quality of economic evaluations in systematic reviews. The
project team also provided a guideline to the criteria list items
to standardize its interpretation and facilitate its use. Using
this criteria list will make future systematic reviews of eco-
nomic evaluations more transparent, informative, and com-
parable. Consequently, the CHEC-list can help researchers
and policy-makers to interpret the results of systematic re-
views more easily and can be of help by translating these
results into policy implications.
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